Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Thomas Eggermann, Dorte Launholt Lildballe, Martine Cools, Bernadette P. M. van Nesselrooij, Vassos Neocleous, Pavlos Fanis, Athanasia Stoupa, Federico Baronio, Anne Barlier, Corinna Grasemann, Marco Bonomi, Ronald R. de Krijger, Soara Menabò, Adrian Daly, Sofia Asioli, Susan O´Connell, Pedro Marques, Gérald Raverot, Federico Gatto, Nienke Ruurdje Biermasz, Iris C. M. Pelsma, Daniëlle C M van der Kaay, Claus Højbjerg Gravholt, Luca Persani, Dirk Prawitt
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders
10.1038/s41431-018-0099-1 · 2018
Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients
10.1016/j.gim.2023.100880 · 2023
International guideline on genetic testing of children with short stature
10.1093/ejendo/lvag013 · 2026
The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among endo-ERN centres
10.1530/ec-22-0367 · 2022
Diagnosis and management of Silver-Russell syndrome: first international consensus statement
10.1038/nrendo.2016.138 · 2017
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement
10.1038/s41574-018-0042-0 · 2018
Hypoparathyroidism: genetics and diagnosis
10.1002/jbmr.4667 · 2022
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice
10.1016/s2213-8587(25)00119-6 · 2025
2024 European thyroid association guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action
10.1530/etj-24-0125 · 2024
Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement
10.1038/s41574-026-01291-4 · 2026
Recommendations for whole genome sequencing in diagnostics for rare diseases
10.1038/s41431-022-01113-x · 2022
Unresolved referenced work
2022
A nationally agreed cross-professional competency framework to facilitate genomic testing
10.1016/j.gim.2022.04.023 · 2022
Approaches to quality management and accreditation in a genetic testing laboratory
10.1038/ejhg.2010.104 · 2010
Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (endo-ERN)
10.1186/s13023-020-01420-w · 2020
Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the association for molecular pathology and the college of American pathologists
10.1016/j.jmoldx.2017.11.003 · 2018
A practical guide to genetic testing in endocrinology
10.1111/cen.14596 · 2022
Clinical genetic testing in endocrinology: current concepts and contemporary challenges
10.1111/cen.14053 · 2019
Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes
10.1007/s12020-021-02636-x · 2021
GestaltMatcher facilitates rare disease matching using facial phenotype descriptors
10.1038/s41588-021-01010-x · 2022
Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings
10.1038/s41588-024-01836-1 · 2024
Polygenic risk scores: an overview from bench to bedside for personalised medicine
10.3389/fgene.2022.1000667 · 2022
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
10.1016/j.annonc.2022.12.003 · 2023
Integrated genomic characterization of papillary thyroid carcinoma
10.1016/j.cell.2014.09.050 · 2014
Molecular genetics and diagnosis of thyroid cancer
10.1038/nrendo.2011.142 · 2011
Targeted mutational analysis of cortisol-producing adenomas
10.1210/clinem/dgab682 · 2022
KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism
10.1210/jc.2019-00531 · 2019
Targeting RET in medullary thyroid cancer
10.1530/erc-24-0291 · 2025
Molecular predictive biomarker testing in advanced thyroid cancer—a European consensus
10.1530/etj-25-0024 · 2025
Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
10.1200/jco.2017.76.8671 · 2018
Detection of circulating tumor DNA in early- and late-stage human malignancies
10.1126/scitranslmed.3007094 · 2014
Liquid biopsies come of age: towards implementation of circulating tumour DNA
10.1038/nrc.2017.7 · 2017
Genotype-phenotype correlation and challenges in mutation detection in McCune-albright syndrome: a retrospective study of a French cohort
10.1016/j.ando.2026.102514 · 2026
Genome architecture in endocrine diseases: X-linked Acrogigantism (X-LAG) syndrome
10.1016/j.ando.2026.102511 · 2026
SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the Study of Adrenal Tumors (ENS@T)
10.1038/modpathol.2015.41 · 2015
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas
10.1172/jci84894 · 2016
Mutations in the deubiquitinase gene USP8 cause Cushing's disease
10.1038/ng.3166 · 2015
Next generation sequencing in endocrine practice
10.1016/j.ymgme.2015.05.002 · 2015
GENETICS IN ENDOCRINOLOGY: genetic diagnosis of endocrine diseases by NGS: novel scenarios and unpredictable results and risks
10.1530/eje-18-0379 · 2018
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
10.1038/gim.2015.30 · 2015
EndoCompass project: research roadmap for growth disorders
10.1093/ejendo/lvaf070 · doi-reference
EndoCompass project: research roadmap for growth disorders
10.1159/000549204 · doi-reference
Recommendations for reporting results of diagnostic genomic testing
10.1038/s41431-022-01091-0 · doi-reference
SHBG gene polymorphisms and their influence on serum SHBG, total and free testosterone concentrations in men
10.1210/clinem/dgae280 · doi-reference
A framework for reporting secondary and incidental findings in prenatal sequencing: when and for whom?
10.1002/pd.6097 · doi-reference
Points to consider for informed consent for genome/exome sequencing
10.1038/gim.2013.94 · doi-reference
Stakeholder views on opportunistic genomic screening in The Netherlands: a qualitative study
10.1038/s41431-021-00828-7 · doi-reference
Correspondence on “ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)” by Miller et al
10.1016/j.gim.2021.10.020 · doi-reference
Informed consent in the genomics era
10.1101/cshperspect.a036582 · doi-reference
Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings
Confidence 0%
10.1007/s00439-020-02220-9 · doi-reference
Deutsche gesellschaft für humangenetik e.V. (GfH). 24102023 stellungnahme der deutschen gesellschaft für humangenetik zu zusatz- und zufallsbefunden in der genetischen diagnostik
10.1515/medgen-2023-2060 · doi-reference
Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations
10.1038/s41431-018-0224-1 · doi-reference
Opportunistic genomic screening. Recommendations of the European society of human genetics
10.1038/s41431-020-00758-w · doi-reference
Reassessment of genomic sequence variation to harmonize interpretation for personalized medicine
10.1016/j.ajhg.2016.09.015 · doi-reference
Reassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis
10.1093/ejendo/lvaf044 · doi-reference
Reanalysis and reclassification of rare genetic variants associated with inherited arrhythmogenic syndromes
10.1016/j.ebiom.2020.102732 · doi-reference
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
10.1038/gim.2013.73 · doi-reference
ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American college of medical genetics and genomics (ACMG)
10.1016/j.gim.2025.101454 · doi-reference
Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)
10.1038/s41436-021-01139-4 · doi-reference
Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines
10.1002/humu.24088 · doi-reference
Clinical variant reclassification in hereditary disease genetic testing
10.1001/jamanetworkopen.2024.44526 · doi-reference
Variant reclassification and clinical implications
10.1136/jmg-2023-109488 · doi-reference
Guidelines for clinical interpretation of variant pathogenicity using RNA phenotypes
10.1002/humu.24416 · doi-reference